NAS:VTRS (USA)
Business Description
Viatris Inc
NAICS : 325411
SIC : 2833
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Compare
Compare
Traded in other countries / regions
MYL.Austria
•
VIA.Germany
•
MYL.Israel
•
MYL.Mexico
•
MYL1.Switzerland
•
0A5V.UK
•
VTRS.USA
Description
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 1.07 | |||||
| Debt-to-EBITDA | 4.5 | |||||
| Interest Coverage | 3.1 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 0.89 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -12.6 | |||||
| 3-Year EBITDA Growth Rate | -13.4 | |||||
| 3-Year FCF Growth Rate | -2.2 | |||||
| 3-Year Book Growth Rate | -10.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -4.14 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.67 | |||||
| 9-Day RSI | 77.59 | |||||
| 14-Day RSI | 67.84 | |||||
| 6-1 Month Momentum % | -35.7 | |||||
| 12-1 Month Momentum % | -34.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 0.98 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 137.55 | |||||
| Days Sales Outstanding | 77.46 | |||||
| Days Payable | 37.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.14 | |||||
| Dividend Payout Ratio | 0.73 | |||||
| Forward Dividend Yield % | 4.32 | |||||
| 5-Year Yield-on-Cost % | 4.14 | |||||
| 3-Year Average Share Buyback Ratio | -32.9 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.37 | |||||
| Operating Margin % | 10.69 | |||||
| Net Margin % | 4.43 | |||||
| ROE % | 3.69 | |||||
| ROA % | 1.39 | |||||
| ROIC % | 3.04 | |||||
| ROC (Joel Greenblatt) % | 21.43 | |||||
| ROCE % | 3.33 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.63 | |||||
| Forward PE Ratio | 3.25 | |||||
| PE Ratio without NRI | 17.63 | |||||
| Shiller PE Ratio | 11.45 | |||||
| Price-to-Owner-Earnings | 5.69 | |||||
| PS Ratio | 0.78 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Free-Cash-Flow | 4.44 | |||||
| Price-to-Operating-Cash-Flow | 3.8 | |||||
| EV-to-EBIT | 22.46 | |||||
| EV-to-Forward-EBIT | 6.08 | |||||
| EV-to-EBITDA | 7.15 | |||||
| EV-to-Forward-EBITDA | 5.57 | |||||
| EV-to-Revenue | 1.97 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | 11.14 | |||||
| Price-to-Projected-FCF | 0.44 | |||||
| Price-to-Median-PS-Value | 0.45 | |||||
| Earnings Yield (Greenblatt) % | 4.45 | |||||
| Forward Rate of Return (Yacktman) % | 9.15 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:VTRS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17,186.7 | ||
| EPS (TTM) ($) | 0.63 | ||
| Beta | 0.92 | ||
| Volatility % | 42.33 | ||
| 14-Day RSI | 67.84 | ||
| 14-Day ATR ($) | 0.357496 | ||
| 20-Day SMA ($) | 10.083 | ||
| 12-1 Month Momentum % | -34.11 | ||
| 52-Week Range ($) | 9.445 - 15.6 | ||
| Shares Outstanding (Mil) | 1,212.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viatris Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||